Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B‐cell lymphoma patients who are HBsAg‐negative/ HBcAb‐positive: a multicenter retrospective study

Abstract

The present study revealed a low HBV reactivation rate of 2.3% in prior resolved hepatitis B among DLBCL patients undergoing RCHOP-like therapy.

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

“…In another Asian study only one (2.3%) of 43 DLBCL patients treated with an R-CHOP regimen showed reactivation of HBV replication [73] , for which a remission was obtained with antiviral therapy with no need to discontinue chemotherapy. Koo et al [74] described HBV reactivation in two (3%) of 62 HBsAg-negative/ anti-HBc-positive patients treated with rituximab-based chemotherapy who did not undergo anti-HBV prophylaxis.…”

Patients with hematological malignancies and serological signs of prior resolved hepatitis B

“…We retrieved data on the prevalence of serological stigmata of prior resolved hepatitis B infection in patients with HM, predominantly lymphomas. In this population, median antiHBc antibodies prevalence is high: 18.8% in Italy (range 6.3%-56%) [8,14,[36][37][38][39][40][41][42] ; 44.2% in China (17%-62.3%) [30,33,[43][44][45] ; and 24.3% in Japan (range 13.7%-37.8%) [25,35,46] . These percentages of pOBI are higher than those reported for HBsAg positivity in similar populations from the same countries, respectively a 4.4%-8.5% range for Italy [8,40] , a median 24.5% for China (range: 21%-27%) [20,45,47,48] and 4.1% for Japan (range: 2%-12.6%) [25,46,49,50] .…”

“…The median reported incidence of HBV reactivation in pOBI patients treated for HM is 4.5% (range: 0.72%-50%) [20,25,30,33,[35][36][37]40,42,[44][45][46]51,52] . The reported rate of mortality as a consequence of reactivation is variable, with 64% of studies examined not describing any mortality [25,[35][36][37]40,42,44,46,52] , while the remaining 36% report a median value of 50% (range 14.3%-100%) [20,30,33,45,51] .…”

Factors associated with hepatic dysfunction in hepatitis B-positive patients with postgastrectomy adenocarcinoma

“…Chronic HBV infection is a major public health problem in Asian countries and the reactivation of HBV prior to or following treatment with immunosuppressive or anticancer agents has been documented since 1975 (6,16). The most commonly reported types of chemotherapy associated with HBV reactivation are those used for the treatment of hematological malignancies, including acute leukemia, myeloproliferative disorders, lymphoproliferative disorders and plasma cell dyscrasias (17)(18)(19).…”

“…Investigation into the influence of radiotherapy on HBV reactivation in gastric cancer patients is needed. Chemoradiation treatment is unable to cause HBV reactivation in all the cancer patients who have hepatitis B (16,23) and the patients who did not develop HBV reactivation may also have hepatic dysfunction. Therefore, we studied the associating factors of hepatic function in 44 postgastrectomy patients who carried HBV and were treated in our department.…”